-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8BIO Publishes Presentation on Glioblastoma Cell Therapy Research

PUBT·11/16/2026 16:56:05
Diffusion vocale
IN8BIO Publishes Presentation on Glioblastoma Cell Therapy Research
  • IN8BIO published its SNO 2026 presentation on glioblastoma trials involving 17 patients.
  • Repeat-dose patients had median overall survival of 20.9 months; median progression-free survival reached 13 months.
  • Two-year survival was 50% among the 14 repeat-dose patients.
  • No treatment-related serious adverse events or treatment-related deaths were reported.
  • Enrollment was suspended in 2024 because of funding constraints; data collection on enrolled patients continues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.